449 Results for "

PD-L

" in MedChemExpress (MCE) Product Catalog:
Products (449)

449 Results for "PD-L" in MCE Product Catalog:

72
Cilengitide
Cilengitide
0 Images
72 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Target:  

Integrin Autophagy Apoptosis STAT PD-1/PD-L1

Domaines de recherche:  

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
38
Atezolizumab
Atezolizumab
0 Images
38 Cited Publications
Cat. No.: HY-P9904
CAS No.: 1380723-44-3
Synonyms: MPDL3280A; RG-7446; RO-5541267

Target:  

PD-1/PD-L1 Apoptosis Autophagy

Domaines de recherche:  

Cancer

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
32
BMS-1
BMS-1
0 Images
32 Cited Publications
Cat. No.: HY-19991
CAS No.: 1675201-83-8
Synonyms: PD-1/PD-L1 inhibitor 1
Target:  

PD-1/PD-L1 Apoptosis

Domaines de recherche:  

Inflammation/Immunology Cancer

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) .
25
BMS-202
BMS-202
0 Images
25 Cited Publications
Cat. No.: HY-19745
CAS No.: 1675203-84-5
Target:  

PD-1/PD-L1 Apoptosis

Domaines de recherche:  

Cancer

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .
25
BMS-202 hydrochloride
BMS-202 hydrochloride
0 Images
25 Cited Publications
Cat. No.: HY-19745B
CAS No.: 2089334-95-0
Target:  

PD-1/PD-L1 Apoptosis

Domaines de recherche:  

Cancer

BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity .
15
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
0 Images
15 Cited Publications
Cat. No.: HY-P99145

Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .
15
Tomivosertib
Tomivosertib
0 Images
15 Cited Publications
Cat. No.: HY-100022
CAS No.: 1849590-01-7
Pureté:  99.92%
Synonyms: eFT508
Target:  

MNK PD-1/PD-L1

Domaines de recherche:  

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
10
Avelumab (anti-PD-L1)
Avelumab (anti-PD-L1)
0 Images
10 Cited Publications
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Pureté:  96.02%

Target:  

PD-1/PD-L1

Domaines de recherche:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
10
Avelumab
Avelumab
0 Images
10 Cited Publications
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Domaines de recherche:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
9
PD-L1 Protein, Human (HEK293)
PD-L1 Protein, Human (HEK293)
0 Images
9 Cited Publications
Cat. No.: HY-P73361
Pureté:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Programmed cell death 1 ligand 1; PD-L1; B7-H1; CD274; PDL1
Species:  
Human
Source:  
HEK293
6
Durvalumab (anti-PD-L1)
Durvalumab (anti-PD-L1)
0 Images
6 Cited Publications
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
6
BMS-1166
BMS-1166
0 Images
6 Cited Publications
Cat. No.: HY-102011
CAS No.: 1818314-88-3
Pureté:  99.49%
Target:  

PD-1/PD-L1

Domaines de recherche:  

Inflammation/Immunology Cancer

BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
6
BMS-1166 hydrochloride
BMS-1166 hydrochloride
0 Images
6 Cited Publications
Cat. No.: HY-102011A
CAS No.: 2113650-05-6
Pureté:  99.31%
Target:  

PD-1/PD-L1

Domaines de recherche:  

Inflammation/Immunology Cancer

BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
6
Durvalumab
Durvalumab
0 Images
6 Cited Publications
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
5
Pembrolizumab (anti-PD-1)
Pembrolizumab (anti-PD-1)
0 Images
5 Cited Publications
Cat. No.: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
4
Fraxinellone
Fraxinellone
0 Images
4 Cited Publications
Cat. No.: HY-N0242
CAS No.: 28808-62-0
Category:  

Dictamnus dasycarpus Turcz. Terpenoids Sesquiterpenes Rutaceae Plants Disease Research Fields Inflammation/Immunology

Target:  

PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT

Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 .
4
Camrelizumab
Camrelizumab
0 Images
4 Cited Publications
Cat. No.: HY-P9971
CAS No.: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210

Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
4
Panaxadiol
Panaxadiol
0 Images
4 Cited Publications
Cat. No.: HY-N0596
CAS No.: 19666-76-3
Synonyms: 20(R)-Panaxadiol
Category:  

Panax ginseng C. A. Meyer Triterpenes Terpenoids Plants Disease Research Fields Araliaceae Cancer

Target:  

PD-1/PD-L1 HIF/HIF Prolyl-Hydroxylase STAT

Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities .
3
AUNP-12
AUNP-12
0 Images
3 Cited Publications
Cat. No.: HY-P1812
CAS No.: 1353563-85-5
Synonyms: NP-12
Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
3
AUNP-12 TFA
AUNP-12 TFA
0 Images
3 Cited Publications
Cat. No.: HY-P1812A
Synonyms: NP-12 TFA
Target:  

PD-1/PD-L1

Domaines de recherche:  

Cancer

AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
Assay Types